A Randomized Phase Ill Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Brief description of study
The purpose of this study is to test the effectiveness and safety of standard chemotherapy drug along with carboplatin, compared to the standard chemotherapy drug without carboplatin. Patients will receive doxorubicin/cyclophosphamide followed by paclitaxel. Carboplatin is FDA-approved for the treatment of cancer and is used for the treatment of breast cancer that has spread. FDA is the U.S Food and Drug Administration, the health authority that gives approval for new medicines to be prescribed in the United States.
Clinical Study Identifier: s18-01785
ClinicalTrials.gov Identifier: NCT02488967
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
